Innate Pharma S.A.
IPHA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $144,020 | $213,067 | $277,259 | $318,971 |
| - Cash | $66,396 | $70,605 | $84,225 | $103,756 |
| + Debt | $30,995 | $39,893 | $42,251 | $44,251 |
| Enterprise Value | $108,619 | $182,355 | $235,285 | $259,466 |
| Revenue | $12,621 | $51,901 | $57,674 | $12,112 |
| % Growth | -75.7% | -10% | 376.2% | – |
| Gross Profit | $12,621 | $5,619 | $6,011 | -$22,301 |
| % Margin | 100% | 10.8% | 10.4% | -184.1% |
| EBITDA | -$46,911 | -$1,839 | -$12,279 | -$43,229 |
| % Margin | -371.7% | -3.5% | -21.3% | -356.9% |
| Net Income | -$49,471 | -$7,570 | -$58,103 | -$52,809 |
| % Margin | -392% | -14.6% | -100.7% | -436% |
| EPS Diluted | -0.61 | -0.09 | -0.73 | -0.57 |
| % Growth | -577.8% | 87.7% | -28.1% | – |
| Operating Cash Flow | -$6,896 | -$32,558 | -$19,154 | -$58,457 |
| Capital Expenditures | -$391 | -$2,351 | -$1,122 | -$1,330 |
| Free Cash Flow | -$7,287 | -$34,909 | -$20,276 | -$59,787 |